Lung tumouroids as a testing platform for precision CAR T cell therapy.

Area of Science:

• Oncology
• Immunotherapy
• Translational Research

Background:

• Lung cancer remains a leading cause of cancer mortality, with significant challenges in treatment efficacy due to tumor heterogeneity and resistance.
• Standard therapies and chimeric antigen receptor (CAR) T cell therapy face limitations in effectively treating lung cancer.
• Preclinical models are crucial for understanding patient-specific responses and personalizing treatment strategies.

Purpose of the Study:

• To develop and validate a patient-specific preclinical model for studying lung cancer therapy responses.
• To assess the utility of tumouroids and organoids in predicting responses to standard therapies and CAR T cell therapy.
• To investigate mechanisms of resistance to CAR T cell therapy in lung cancer.

Main Methods:

• Generation of matched lung tumouroids and healthy lung organoids from patient samples.
• Comprehensive molecular and histological characterization of tumouroids (genomic, epigenomic, proteomic analyses).
• Evaluation of tumouroid and organoid responses to standard-of-care therapies and patient-specific CAR T cells.

Main Results:

• Lung tumouroids accurately recapitulated the molecular and histological identity of the original tumors.
• The model demonstrated faithful replication of individual patient responses to standard therapies.
• Patient-specific CAR T cell responses were revealed, highlighting the interplay between antigen density and intrinsic tumor resistance mechanisms.

Conclusions:

• Patient-derived tumouroids and organoids provide a robust platform for personalized lung cancer therapy research.
• This model supports rational patient selection for CAR T cell therapy in lung cancer.
• The framework facilitates the design of CAR T cells engineered to overcome resistance in solid tumors.